Probo Medical Names Michael Asmer as Chairman and Greg Kopulos as CEO
"I am tremendously proud of what our team has accomplished over the last five years at Probo and am also excited for what lies ahead," stated Asmer. "With the integration of recent acquisitions, Probo enters a new phase of growth where we can support our customers with a comprehensive offering of diagnostic imaging solutions."
"Probo is well on its way to becoming a global leader in diagnostic imaging solutions. I am humbled and excited to build on the great work of Michael and the entire Probo team," remarked Kopulos. "With the continued investment in and integration of our prior acquisitions, Probo has never been better positioned to help our customers deliver quality care to their patients while providing needed cost savings."
Probo Medical is backed by Avista Healthcare Partners, a leading private equity firm focused exclusively on healthcare with over
About Probo Medical
Probo Medical is a global diversified solutions provider of diagnostic imaging products and services, including equipment sales, service, rental, repair and installation. For more information about Probo Medical, visit http://www.probomedical.com.
Contacts
For Probo Medical:
Contact:
Email: [email protected]
For Avista Healthcare Partners:
Kekst CNC
[email protected] / [email protected]
View original content:https://www.prnewswire.com/news-releases/probo-medical-names-michael-asmer-as-chairman-and-greg-kopulos-as-ceo-302247040.html
SOURCE Probo Medical
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HeartX Cardiovascular Accelerator Announces Five Startup Companies Selected for the 2026 Program
- DrugBank Brings Grounded Biopharma Intelligence to Microsoft Copilot
- ProgenyHealth Appoints Melanie Bella to Board of Managers and Alec DiDonato as Chief Operating Officer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share